MindMed Provides Overview Of Clinical Progress And Corporate Updates At Investor Day
Portfolio Pulse from Happy Mohamed
Mind Medicine (MindMed) Inc will provide an overview of clinical progress and corporate updates during an Investor Day focused on the MM-120 program in generalized anxiety disorder (GAD). The Phase 2b trial evaluating MM-120 for the treatment of GAD remains on track for a late 2023 topline data readout.
June 20, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
MindMed's Investor Day will provide updates on the MM-120 program in GAD, with the Phase 2b trial on track for a late 2023 topline data readout.
The Investor Day will provide updates on MindMed's MM-120 program in GAD, which is important for investors to understand the company's progress. However, the short-term impact on the stock price is neutral as the Phase 2b trial data readout is still more than a year away.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100